Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial.
ablation technique
endoscopic ultrasonography
pancreatic cancer
randomized controlled trial
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Sep 2021
08 Sep 2021
Historique:
received:
01
08
2021
revised:
31
08
2021
accepted:
01
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Endoscopic ultrasound-ablation with HybridTherm-Probe (EUS-HTP) significantly reduces tumour volume (TV) in locally-advanced pancreatic ductal adenocarcinoma (LA-PDAC). We aimed at investigating the clinical efficacy of EUS-HTP plus chemotherapy versus chemotherapy (HTP-CT and CT arms) in LA- and borderline-resectable (BR) PDAC, with 6-months progression-free survival (6-PFS) rate as primary endpoint. In a phase-II randomized-controlled-trial, 33 LA/BR-PDAC patients per-arm were planned to verify 20% improved 6-PFS rate. Radiological response (Choi criteria), TV and serum CA19.9 were assessed up to 6-months. Seventeen and 20 LA/BR-PDAC patients were randomized to HTP-CT or CT. Baseline and CT-related features were balanced. At 6-months, 6-PFS rate was 41.2% and 30% in HTP-CT and CT arms (
Identifiants
pubmed: 34572743
pii: cancers13184512
doi: 10.3390/cancers13184512
pmc: PMC8464946
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pancreas. 2013 Oct;42(7):1143-9
pubmed: 23899940
Cancer. 2009 Jun 15;115(12):2630-9
pubmed: 19353729
Gastrointest Endosc. 2016 Feb;83(2):440-3
pubmed: 26344883
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
Gastrointest Endosc. 2012 Dec;76(6):1142-51
pubmed: 23021160
Langenbecks Arch Surg. 2018 Mar;403(2):213-220
pubmed: 28983662
Surgery. 2011 Sep;150(3):466-73
pubmed: 21878232
J Gastrointestin Liver Dis. 2018 Mar;27(1):67-72
pubmed: 29557417
Int J Hyperthermia. 2018;35(1):398-418
pubmed: 30428728
Endosc Int Open. 2020 Oct;8(10):E1511-E1519
pubmed: 33043122
Sci Rep. 2018 Jul 10;8(1):10383
pubmed: 29991730
Lancet Gastroenterol Hepatol. 2018 Oct;3(10):691-697
pubmed: 30220407
Ther Adv Med Oncol. 2020 Sep 16;12:1758835920953294
pubmed: 32983266
AJR Am J Roentgenol. 2016 Aug;207(2):282-8
pubmed: 27249174
Diagn Interv Imaging. 2017 Sep;98(9):651-659
pubmed: 28579522
Int J Hyperthermia. 2019 Oct;36(2):53-58
pubmed: 31537162
Ann Palliat Med. 2021 Feb;10(2):1842-1850
pubmed: 33440967
Endosc Ultrasound. 2020 Mar-Apr;9(2):83-100
pubmed: 32295966
Br J Surg. 2015 Feb;102(3):182-93
pubmed: 25524417
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210
pubmed: 30865919
Semin Oncol. 2021 Feb;48(1):95-105
pubmed: 33608132
Endosc Ultrasound. 2021 Sep-Oct;10(5):398-399
pubmed: 34003141
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Oncol Lett. 2015 Jun;9(6):2680-2686
pubmed: 26137128
Br J Surg. 2017 Apr;104(5):600-607
pubmed: 28177521
J Clin Oncol. 2011 Nov 1;29(31):4105-12
pubmed: 21969502
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
J Gastrointest Oncol. 2017 Jun;8(3):566-571
pubmed: 28736643
Arch Pathol Lab Med. 2012 Jan;136(1):100-9
pubmed: 22208494
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
J Natl Compr Canc Netw. 2016 Apr;14(4):450-73
pubmed: 27059193
Sci Rep. 2017 Jun 13;7(1):3437
pubmed: 28611425
Ann Oncol. 2008 Sep;19(9):1592-9
pubmed: 18467316
Surg Endosc. 2018 Sep;32(9):4022-4028
pubmed: 29766302
Radiology. 2012 May;263(2):409-18
pubmed: 22438364
Oncologist. 2014 Apr;19(4):394-402
pubmed: 24652387